Mission and Vision

Accelerating the Adoption of Decentralized Clinical Trials

Group 8

Mission

DTRA  enables collaboration between stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare.

Group 8

Vision

DTRA’s vision is to make research participation accessible to everyone. This is enabled by the consistent, widespread adoption of appropriate decentralized research methods.

Group 8

Hear from our Members

Discover ways to get involved with DTRA. Join our working groups, attend our events, and participate in our online community to share your experiences and learn from others.

Component 7 – 1

DTRA is aligning all of the stakeholders - where everyone gets a voice. We are collectively determining what we need to do to make adoption easy and trials accessible to everyone. All of the initiatives have been driven by a diverse group of stakeholders, and the regulatory agencies have participated as well. This will give the industry a full view on what needs to happen in order to succeed and ultimately include the desired and diverse populations into clinical trials.

Caroline Redeker, Advanced Clinical

Component 7 – 1

Organizations like DTRA leverage the power of the collective, the brain power of all the leaders in these different pharma companies, to help all of us collectively improve so that ultimately we deliver value for the community, for patients, for the world. And I think DTRA is in the unique position to help accelerate the adoption of decentralized trials so that in five, ten, fifteen years, decentralized trials become a normal thing for clinical trials. Hopefully then we can then compare that future with the past and see how much we have accelerated clinical trials, how much we have created more access for patients and how much we delivered more value in terms of healthcare for the world.

Hassan Kadhim, Bristol-Myers Squibb

Component 7 – 1

What I love about DTRA is the fact that we all came together in a very easy way. The need was there and entry to the DTRA was easy. As a result, you see that the members in our industry joined because we understand the problem we all want to solve for. All that brain power is here and we're sharing that knowledge without any constraints, without legal, as we’re not competing on the science. I love the networking, the collaboration, and these conversations that enable us to empower each other to serve our patients.

Munther Baara, Edetek

Component 7 – 1

DTRA is like a community fish bowl. And from that perspective, the reason you want their access and their insight is because they have done many of these things in their daily lives or are still doing it and have a vast network of stakeholders that can provide value back to you from intellectual knowledge as well as best practices and know-how. To join DTRA is really expanding your knowledge base. You're not getting the collective power of one entity or two, you're getting the overall power of more than 100 entities. and this is really the value you get from joining DTRA.

Mo Ali, Medable

Component 7 – 1

DTRA is really important because it brings together all the stakeholders in decentralized clinical trials, it allows us to grow and get better together to standardize on the use of words and vocabulary and processes. and also we can learn from each other and continue to innovate along the way.

Kelly McKee, Medidata